Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Calidi Biotherapeutics, Inc. (CLDI)
USD0.12
0.00 (-1.23%)
US AMEX Healthcare Biotechnology
Address
4475 Executive Drive 92121
San Diego, CA, US
San Diego, CA, US
CEO
Eric E. Poma
Website
calidibio.com
IPO
2021-11-01
CIK 1855485 ISIN US3207034089
Also trades on
New York Stock Exchange Arca · CLDI (USD)
New York Stock Exchange Arca · FLAG (USD)
Description
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.12
0.00 (-1.23%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
1.31
Float Shares
5.50M
Free Float %
74.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.26% | -9.90% | -32.51% | -75.25% | -87.63% | -84.14% | -96.30% | -99.99% | -99.98% | -99.98% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.12
Low
2.00
+1,559.8%
Consensus
5.50
+4,464.3%
Median
5.50
+4,464.3%
High
9.00
+7,368.9%
DCF (Unlevered)
0.57
+375.6%
DCF (Levered)
0.71
+485.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
5.50
+4,464.3%
|
Quality scores
Altman Z-Score
-27.51
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+83.3% ★ Q1'26: +80.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-2,799.5% Q1'26: +42,943.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+547.5% Q1'26: +358.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.14× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
7.29M
7.29M – 7.29M
|
| EBITDA |
-19.73M
|
-18.59M
|
—
— – —
|
—
— – —
|
1.46M
1.46M – 1.46M
|
| EBIT |
-21.26M
|
-20.24M
|
—
— – —
|
—
— – —
|
1.46M
1.46M – 1.46M
|
| Net Income |
-22.14M
est: -29.46M (+24.8%)
|
-19.91M
est: -32.01M (+37.8%)
|
-23.75M
-23.75M – -23.75M
+25.8% YoY
|
-20.65M
-20.65M – -20.65M
+13.0% YoY
|
-20.13M
-20.13M – -20.13M
+2.5% YoY
|
| SGA |
12.90M
|
10.50M
|
—
— – —
|
—
— – —
|
531.19M
531.19M – 531.19M
|
| EPS |
-35.70
est: -44.34 (+19.5%)
|
-5.95
est: -7.44 (+20.0%)
|
-5.52
-5.52 – -5.52
+25.8% YoY
|
-4.80
-4.80 – -4.80
+13.0% YoY
|
-4.68
-4.68 – -4.68
+2.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.28M
OE per share TTM
-3.66
Owner's Yield
-955.38%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2,501.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
13
Total invested
104.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cable Car Capital LLC (3) | 897.2K | 9.99% | 897.2K | — | 897.2K | — | IA, PN | Delaware | 2024-09-11 | ↗ |
| 2 | Funicular Funds, LP | 897.2K | 9.99% | 897.2K | — | 897.2K | — | PN | Delaware | 2024-09-11 | ↗ |
| 3 | Jacob Ma-Weaver (3) | 897.2K | 9.99% | 897.2K | — | 897.2K | — | IN | Delaware | 2024-09-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
13
-14 vs prev Q
New positions
3
Closed positions
17
Increased
6
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DRW SECURITIES, LLC | 147.8K +147.8K (+100.0%) | 172.9K +172.9K (+100.0%) | 3.01% +3.011 pp | 0.00% +0.005 pp | USD1.17 +0.0% | 1 qtrs NEW |
| 2 | HIGHTOWER ADVISORS, LLC | 83.5K -1.4K (-1.7%) | 97.7K -31.4K (-24.3%) | 1.70% -0.029 pp | 0.00% +0.000 pp | USD1.52 -23.0% | 2 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 41.9K +12.3K (+41.7%) | 49.1K +4.1K (+9.1%) | 0.85% +0.251 pp | 0.00% +0.000 pp | USD1.42 -17.6% | 2 qtrs — |
| 4 | VANGUARD GROUP INC | 34.7K +— (+0.0%) | 40.6K -12.2K (-23.0%) | 0.71% +0.000 pp | 0.00% +0.000 pp | USD1.52 -23.0% | 2 qtrs — |
| 5 | FMR LLC | 22.0K +21.9K (+17,510.4%) | 25.8K +25.6K (+13,455.3%) | 0.45% +0.446 pp | 0.00% +0.000 pp | USD1.17 +0.0% | 2 qtrs — |
| 6 | VIRTU FINANCIAL LLC | 21.2K +21.2K (+100.0%) | 25.0K +25.0K (+100.0%) | 0.43% +0.433 pp | 0.00% +0.001 pp | USD1.17 +0.0% | 1 qtrs NEW |
| 7 | RS CRUM INC. | 20.3K +5.0K (+32.8%) | 23.7K +510.0 (+2.2%) | 0.41% +0.102 pp | 0.00% 0.000 pp | USD1.43 -18.2% | 2 qtrs — |
| 8 | NORTHERN TRUST CORP | 17.8K +17.8K (+100.0%) | 20.8K +20.8K (+100.0%) | 0.36% +0.362 pp | 0.00% +0.000 pp | USD1.17 +0.0% | 1 qtrs NEW |
| 9 | JANE STREET GROUP, LLC | 11.5K +11.5K (+100.0%) | 13.4K +13.4K (+100.0%) | 0.23% +0.234 pp | 0.00% +0.000 pp | USD1.17 +0.0% | 1 qtrs NEW |
| 10 | FARTHER FINANCE ADVISORS, LLC | 10.0K +10.0K (+100.0%) | 11.7K +11.7K (+100.0%) | 0.20% +0.204 pp | 0.00% +0.000 pp | USD1.17 +0.0% | 1 qtrs NEW |
| 11 | UBS GROUP AG | 7.5K +5.0K (+193.1%) | 8.8K +4.9K (+125.6%) | 0.15% +0.101 pp | 0.00% +0.000 pp | USD1.29 -9.3% | 2 qtrs — |
| 12 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.8K +2.8K (+100.0%) | 3.2K +3.2K (+100.0%) | 0.06% +0.057 pp | 0.00% +0.000 pp | USD1.17 +0.0% | 1 qtrs NEW |
| 13 | ADVISOR GROUP HOLDINGS, INC. | 2.1K +2.0K (+1,332.7%) | 2.5K +2.2K (+980.3%) | 0.04% +0.040 pp | 0.00% +0.000 pp | USD1.19 -1.7% | 2 qtrs — |
| 14 | MORGAN STANLEY | 1.5K +1.1K (+279.1%) | 1.7K +1.1K (+191.8%) | 0.03% +0.022 pp | 0.00% +0.000 pp | USD1.26 -7.1% | 2 qtrs — |
| 15 | FINEPOINT CAPITAL LP | 1.0K +— (+0.0%) | 1.2K -365.0 (-23.0%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.52 -23.0% | 2 qtrs — |
| 16 | APOLLO MANAGEMENT HOLDINGS, L.P. | 1.0K +— (+0.0%) | 1.2K -364.0 (-23.0%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.52 -23.0% | 2 qtrs — |
| 17 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 1.0K +— (+0.0%) | 1.2K -365.0 (-23.1%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.52 -23.0% | 2 qtrs — |
| 18 | BARRETT & COMPANY, INC. | 292.00 +— (+0.0%) | 342.00 -102.0 (-23.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.52 -23.0% | 2 qtrs — |
| 19 | TRADEWINDS CAPITAL MANAGEMENT, LLC | 101.00 +— (+0.0%) | 119.00 -35.0 (-22.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.51 -22.5% | 2 qtrs — |
| 20 | REYES FINANCIAL ARCHITECTURE, INC. | 100.00 +— (+0.0%) | 117.00 -35.0 (-23.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.52 -23.0% | 2 qtrs — |
| 21 | SBI SECURITIES CO., LTD. | 46.00 +— (+0.0%) | 54.00 -16.0 (-22.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.50 -22.0% | 2 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 46.00 +16.0 (+53.3%) | 53.00 +7.0 (+15.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.37 -14.6% | 2 qtrs — |
| 23 | CVA FAMILY OFFICE, LLC | 42.00 +— (+0.0%) | 49.00 -15.0 (-23.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.50 -22.0% | 2 qtrs — |
| 24 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 28.00 +28.0 (+100.0%) | 33.00 +33.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.14 +2.6% | 1 qtrs NEW |
| 25 | EVERMAY WEALTH MANAGEMENT LLC | 1.00 +— (+0.0%) | 2.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +17.0% | 2 qtrs — |
| 26 | CITIGROUP INC | 1.00 +1.0 (+100.0%) | 1.00 +1.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +17.0% | 1 qtrs NEW |
| 27 | WARBERG ASSET MANAGEMENT LLC | — -18.7K (-100.0%) | — -28.4K (-100.0%) | 0.00% -0.381 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 28 | JPMORGAN CHASE & CO | — -9.0 (-100.0%) | — -14.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 29 | ROYAL BANK OF CANADA | — -417.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.009 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 30 | BELPOINTE ASSET MANAGEMENT LLC | — -20.8K (-100.0%) | — -31.6K (-100.0%) | 0.00% -0.424 pp | 0.00% -0.001 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 4.6K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
15
Sells
0
Shares acquired
1.11M
Shares disposed
—
Cash buys
8.00
Cash sales
—
Net activity
+1,105,727
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-12 | Camaisa Allan | Director | S-Sale | D | Common Stock | 850 | 1.46 | 1.2K | 76,952 | I | ↗ |
| 2025-09-03 | Poma Eric E | Officer | A-Award | A | Stock Options (right to buy) | 10,000 | 1.58 | 15.8K | 10,000 | D | ↗ |
| 2025-09-03 | Jackson Andrew C. | Officer | A-Award | A | Stock Options (right to buy) | 30,000 | 1.58 | 47.4K | 30,000 | D | ↗ |
| 2025-09-03 | Fernandez Santidrian Antonio | Officer | A-Award | A | Stock Options (right to buy) | 35,000 | 1.58 | 55.3K | 35,000 | D | ↗ |
| 2025-08-21 | Schoeneck James A | Director | P-Purchase | A | Warrant (right to buy) | 75,000 | 2.00 | 150.0K | 75,000 | D | ↗ |
| 2025-08-21 | Poma Eric E | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 2.00 | 50.0K | 25,000 | D | ↗ |
| 2025-08-21 | Leftwich Scott | Director | P-Purchase | A | Warrant (right to buy) | 125,000 | 2.00 | 250.0K | 125,000 | D | ↗ |
| 2025-08-21 | Jackson Andrew C. | Officer | P-Purchase | A | Common Stock | 2,500 | 2.00 | 5.0K | 2,500 | D | ↗ |
| 2025-08-20 | Lincoln Alternative Strategies LLC | 10% Owner | — | — | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 730,000 | D | ↗ |
| 2025-07-09 | Stewart Alan R. | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 137,078 | 0.70 | 96.0K | 137,078 | D | ↗ |
| 2025-07-09 | Schoeneck James A | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 164,493 | 0.70 | 115.1K | 164,493 | D | ↗ |
| 2025-07-09 | Peoples George | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 137,078 | 0.70 | 96.0K | 137,078 | D | ↗ |
| 2025-07-09 | Leftwich Scott | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 137,078 | 0.70 | 96.0K | 137,078 | D | ↗ |
| 2025-04-22 | Poma Eric E | Director / Officer | A-Award | A | Stock Option (right to buy) | 726,412 | 0.47 | 340.7K | 726,412 | D | ↗ |
| 2024-12-31 | Stewart Alan R. | Director | A-Award | A | Common Stock | 12,771 | 0.00 | — | 28,976 | D | ↗ |
| 2024-12-31 | Leftwich Scott | Director | A-Award | A | Common Stock | 11,684 | 0.00 | — | 67,774 | D | ↗ |
| 2024-12-17 | Camaisa Allan | Director / Officer | S-Sale | D | Common Stock | 10,000 | 1.62 | 16.2K | 66,712 | D | ↗ |
| 2024-09-26 | Camaisa Allan | Director / Officer / 10% Owner | A-Award | A | Common Stock | 70,155 | 1.15 | 80.7K | 76,712 | D | ↗ |
| 2024-09-20 | Stewart Alan R. | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 20,217 | 1.09 | 22.0K | 20,217 | D | ↗ |
| 2024-09-20 | Schoeneck James A | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 20,217 | 1.09 | 22.0K | 20,217 | D | ↗ |
| 2024-09-20 | Peoples George | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 20,217 | 1.09 | 22.0K | 20,217 | D | ↗ |
| 2024-09-20 | Leftwich Scott | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 20,217 | 1.09 | 22.0K | 20,217 | D | ↗ |
| 2024-07-01 | Peoples George | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 30,904 | 0.19 | 6.0K | 30,904 | — | ↗ |
| 2024-06-28 | Stewart Alan R. | Director | A-Award | A | Common Stock | 73,437 | 0.00 | — | 154,087 | — | ↗ |
| 2024-06-28 | Schoeneck James A | Director | A-Award | A | Common Stock | 79,687 | 0.00 | — | 1,071,781 | — | ↗ |
| 2024-06-28 | Leftwich Scott | Director | A-Award | A | Common Stock | 67,187 | 0.00 | — | 560,873 | — | ↗ |
| 2024-06-17 | Minev Boris Radoslavov | Officer | A-Award | A | Stock Options (right to buy) | 31,360 | 0.20 | 6.1K | 31,360 | — | ↗ |
| 2024-06-17 | Jackson Andrew C. | Officer | A-Award | A | Stock Options (right to buy) | 300,000 | 0.20 | 58.5K | 300,000 | — | ↗ |
| 2024-06-17 | Campbell Wendy Pizarro | Officer | A-Award | A | Stock Options (right to buy) | 60,000 | 0.20 | 11.7K | 60,000 | — | ↗ |
| 2024-06-17 | Camaisa Allan | Director / Officer / 10% Owner | A-Award | A | Stock Options (right to buy) | 40,000 | 0.22 | 8.6K | 40,000 | — | ↗ |
| 2024-06-03 | Schoeneck James A | Director | A-Award | A | Warrants | 548,000 | 0.30 | 164.4K | 548,000 | — | ↗ |
| 2024-04-18 | Schoeneck James A | Director | A-Award | A | Common Stock | 375,000 | 0.40 | 150.0K | 415,887 | — | ↗ |
| 2024-03-29 | Stewart Alan R. | Director | A-Award | A | Common Stock | 25,995 | 0.00 | — | 80,650 | — | ↗ |
| 2024-03-29 | Schoeneck James A | Director | A-Award | A | Common Stock | 28,207 | 0.00 | — | 992,094 | — | ↗ |
| 2024-03-29 | Leftwich Scott | Director | A-Award | A | Common Stock | 23,783 | 0.00 | — | 493,686 | — | ↗ |
| 2024-01-01 | LaPre David | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
7.37M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eric E. Poma | Chief Executive Officer & Director | 565.6K | — |
| Andrew C. Jackson | Chief Financial Officer & Corporate Secretary | 557.6K | male |
| Antonio Fernandez Santidrian | Head of Technical Operations & Chief Scientific Officer | — | — |
| Guy Travis Clifton | Chief Medical Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLDI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
